Response to Commentary on “Pedal Medial Arterial Calcification in Diabetic Foot Ulcers: A Significant Risk Factor of Amputation and Mortality”
Lihong Chen, Dawei Chen, Hongping Gong, Chun Wang, Yun Gao, Yan Li, Weiwei Tang, Panpan Zha, Xingwu Ran

Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsDiabetic Foot Ulcer Assessment and Management · Peripheral Artery Disease Management · Diagnosis and Treatment of Venous Diseases
Dear Editor,
We appreciate the authors for their insightful commentary and for recognizing our manuscript [1] as a valuable contribution that provides crucial insights into the relationship between pedal MAC, the risk of amputation, and mortality in patients with diabetic foot ulcers (DFUs).
We concur that a more sophisticated classification system, such as SINBAD or WIfI systems, could enhance the comprehension of the severity and risk associated with DFUs and improve communication among healthcare professionals. However, considering its simplicity and practicality, the Wagner wound classification system remains internationally recognized and widely utilized.
Regarding laboratory markers, inflammatory biomarkers including erythrocyte sedimentation rate (ESR), C‐reactive protein (CRP), Neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR), and systemic inflammatory response index (SIRI) exhibit significant variability. Specifically, in patients with diabetic foot infections, these inflammatory markers are markedly elevated. Consequently, they serve as indicators of acute infection but are not suitable for assessing long‐term prognosis, such as amputation risk or mortality. Additionally, laboratory markers such as magnesium, zinc, and vitamin B12 are not routinely evaluated in clinical practice. Further research could explore the potential associations between these markers and the prognosis of DFUs.
Because of the longitudinal nature of the study design, participants were followed up over an extended period. The hypoglycemic medications prescribed may have varied over time, making it challenging to incorporate both the medications and their dosages into the analysis. Regarding infections and antibiotics, diabetic foot infection is indeed a recognized risk factor for amputation and short‐term mortality. However, based on our previous meta‐analysis, the primary long‐term causes of mortality include cardiovascular diseases, infections (such as sepsis, respiratory infections, and foot infections), and cancers [2].
We acknowledge that patients with DFUs may concurrently suffer from autoimmune disorders, psychiatric conditions, and malignancies. These comorbidities elevate the risk of amputation and adverse outcomes [3]. However, in this study, we excluded individuals with these comorbidities prior to analysis.
With respect to socioeconomic status and educational attainment, it is well‐established that a lower socioeconomic status constitutes a substantial risk factor for amputation among patients with diabetes and peripheral artery disease [4]. Socioeconomic status, social capital, and medical challenges significantly impede the effective management and prevention of DFUs [5]. Enhanced government intervention is imperative to ensure equitable access to health resources. Additionally, a history of ulceration and prior amputations is a critical risk factor for future amputations and mortality. We concur that these elements must be considered in comprehensive patient care strategies.
Lastly, we fully concur that the follow‐up method of telephone interviews inherently possesses certain limitations. To address this, our diabetic foot care center plans to establish a diabetic foot registry cohort in the future, which will yield more precise and reliable follow‐up data.
In conclusion, we would like to express our gratitude to the authors for their insightful and constructive critiques of our manuscript. In future research endeavors, we aim to incorporate several laboratory markers and risk factors in order to enhance both the management and future investigation of DFUs.
Conflicts of Interest
The authors declare no conflicts of interest.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1L. Chen , D. Chen , H. Gong , et al., “Pedal Medial Arterial Calcification in Diabetic Foot Ulcers: A Significant Risk Factor of Amputation and Mortality,” Journal of Diabetes 16, no. 4 (2024): e 13527, 10.1111/1753-0407.13527.38584152 PMC 10999494 · doi ↗ · pubmed ↗
- 2L. Chen , S. Sun , Y. Gao , and X. Ran , “Global Mortality of Diabetic Foot Ulcer: A Systematic Review and Meta‐Analysis of Observational Studies,” Diabetes, Obesity & Metabolism 25, no. 1 (2023): 36–45, 10.1111/dom.14840.36054820 · doi ↗ · pubmed ↗
- 3M. C. Lu , H. Hsu , C. H. Lin , and M. Koo , “Systemic Vasculitis Is Associated With a Higher Risk of Lower Extremity Amputation in Patients With Severe Peripheral Arterial Occlusive Disease: A Secondary Analysis of a Nationwide, Population‐Based Health Claims Database,” Rheumatology International 37, no. 11 (2017): 1847–1852, 10.1007/s 00296-017-3828-9.28951963 · doi ↗ · pubmed ↗
- 4J. A. Barnes , M. A. Eid , M. A. Creager , and P. P. Goodney , “Epidemiology and Risk of Amputation in Patients With Diabetes Mellitus and Peripheral Artery Disease,” Arteriosclerosis, Thrombosis, and Vascular Biology 40, no. 8 (2020): 1808–1817, 10.1161/ATVBAHA.120.314595.32580632 PMC 7377955 · doi ↗ · pubmed ↗
- 5D. Costa , N. Ielapi , F. Caprino , et al., “Social Aspects of Diabetic Foot: A Scoping Review,” Social Sciences 11, no. 4 (2022): 149, 10.3390/socsci 11040149. · doi ↗
